SCHEMBL2349762

SCHEMBL2349762

Cc1ccc(N2CCN(CCCCn3cc(C)c(=O)[nH]c3=O)CC2)cc1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ADRA1D P25100 1/20 0.56
ADRA1A P35348 1/20 0.56
ADRA1B P35368 1/20 0.56
DRD2 P14416 1/20 0.54
DRD3 P35462 1/20 0.54
HTR7 P34969 5/20 0.49
TK1 P04183 1/20 0.48
TK2 O00142 5/20 0.47
ALDH1A1 P00352 2/20 0.47
KDM4E B2RXH2 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
MAPT P10636 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
TYMP P19971 1/20 0.44
POLB P06746 1/20 0.44
HTR1A P08908 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2352158 0.92 ADRA1D (0.58) ADRA1DADRA1AADRA1BDRD2DRD3
SCHEMBL2352152 0.92 KDM4E (0.54) ADRA1DADRA1AADRA1BDRD2DRD3
SCHEMBL2349854 0.91 HSD17B10 (0.55) ADRA1DADRA1AADRA1BDRD2DRD3
SCHEMBL2347645 0.90 DRD2 (0.57) ADRA1DADRA1AADRA1BDRD2DRD3
SCHEMBL2352931 0.89 DRD2 (0.56) ADRA1DADRA1AADRA1BDRD2DRD3
SCHEMBL2350658 0.89 DRD2 (0.52) ADRA1DADRA1AADRA1BDRD2DRD3
SCHEMBL2353860 0.87 DRD2 (0.55) ADRA1DADRA1AADRA1BDRD2DRD3
SCHEMBL2346664 0.86 DRD2 (0.53) ADRA1DADRA1AADRA1BDRD2DRD3
SCHEMBL2350576 0.85 DRD2 (0.55) ADRA1DADRA1AADRA1BDRD2DRD3
SCHEMBL2346675 0.85 ADRA1D (0.52) ADRA1DADRA1AADRA1BDRD2DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8008488-B2 Pyrimidin-2-one compounds and their use as dopamine D3 receptor ligands ABBOTT GMBH & CO. KG (DE) 2011-08-30 US disclosed
EP-1601659-B1 PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS ABBOTT GMBH & CO KG (DE) 2008-01-16 EP disclosed
US-20060235004-A1 Pyrimidin-2-one compounds and their use as dopamine d3 receptor ligands ABBOT GMBH & CO. KG (DE) 2006-10-19 US disclosed
EP-1601659-A1 PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS Abbott GmbH & Co. KG (DE) 2005-12-07 EP disclosed
WO-2004080981-A1 PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS ABBOTT GMBH & CO. KG (DE) 2004-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060235004-A1 Pyrimidin-2-one compounds and their use as dopamine d3 receptor ligands ADRB3, DRD3, OPRL1 ADRA1D 55/4885ADRA1A 101/4885ADRA1B 78/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.